Navigation Links
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
Date:5/8/2008

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)...XIENCE V in SPIRIT III Trial Experience Better, Lo...rombosis than Patients T...wswire-FirstCall/ -- Long-term data,presented for ...bott,s U.S.,pivotal trial studying the XIENCE(TM) ...trated that XIENCE V continues to deliver clinical...
(Date:5/13/2008)...ce, May 13 /- NicOx S.A.,(E...c. has initiated the,first in a series of planned ... patients, under the companies, collaborative agre...ertensive agents using NicOx,proprietary technolo...rom,the companies, joint research program, of whic...
(Date:5/12/2008)...ucts Expand Infection Prevention Business, DUBLIN...Health, a,global provider of products and services...h care, today announced it has completed the,acqui...the manufacturer of,infection prevention products ...rep(R) brand products are used widely in U.S. hosp...
(Date:5/12/2008)...wswire-USNewswire/ -- The Alliance for Lupus,Resea...resolution,supporting the goals and ideals of Nati...other,s Day. The resolution, introduced by Senator...lls on all Americans to take the,week of May 11th ... on,women,s health issues, and recognizes the impo...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Cardinal Health Completes Enturia Acquisition 2Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2ETH Zurich researchers develop antibody test 2378 1ETH Zurich researchers develop antibody test 2378 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 1Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3660 3Covance to Present at Raymond James 29th Annual Institutional Investors Conference 13260 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 1AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals 13258 2
... HOUSTON, March 20, 2007 - An overexpressed prote...ng forced to devour,themselves, removing one of th...ell growth, researchers at The University of Texas...issue of Molecular,Cancer Research. , The protein ...,TG2, previously has been found by researchers at ...
...Phase 2 Clinical Trials Initiated, CRANBURY, N.J.,...s, a biopharmaceutical company developing small,mo...ones for the,treatment of a range of human genetic...sitive results from its recently completed,Phase 1...rate,AT2101) for Gaucher disease at the of Medica...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 2Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 3
(Date:5/13/2008)...to Serve as Senior Technology Advisor, SALT LAKE ...f Directors,of Sonic Innovations, Inc. (Nasdaq: S...ing aids, today announced that Andrew Raguskus has...us will continue as a member of the,Board of Direc...s a result,of Mr. Raguskus, announcement, the Boar...
(Date:5/13/2008)...NASDAQ: CRME TSX: COM, VANCOUVER, May 13 /PRNewsw...ME / TSX: COM) today reported financial results fo... unless specified otherwise, are,expressed in Cana...ally,Accepted Accounting Principles (Canadian GAAP...hange rate was CAD$1.00=US$0.9742., Results of Op...
(Date:5/13/2008)...itals that treat the poor from improving, study fi... -- The quality of care at hospitals that treat po...et hospitals, is lagging well behind hospitals tha..., These hospitals, which rely on state and fede...t have the money to improve the quality of care at...
(Date:5/13/2008)...y research could slow to a crawl unless regulators...researchers assert in an upcoming opinion piece. ,...fety research. It just isnt the right fit, says Na... at the Johns Hopkins Berman Institute of Bioethic...lished in the June issue of The Joint Commission J...
Breaking Medicine News(10 mins):Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 2Health News:Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 3Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Cardiome Reports First Quarter Results 5Health News:Quality Lags at Safety-Net Hospitals 2Health News:Quality Lags at Safety-Net Hospitals 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3
...t the caffeine content of beverages such as tea, c...u can now clear your suspicion about the decaf lab...e home based kit, produced by researchers at Washi...a dipstick analysis. The results of the present st...
...shop of Canterbury, has warned that National Healt...stem could compromise the quality and centrality o...the Church of England suggested that "short-term e...ervice delivery, and this could put vulnerable peo...
...o enter into partnership with real estate agents t... new homes. // The vicar will offer his services ...ers are intended to cover almost every eventuality...ar in Eccles, Greater Manchester is the pioneer be...
...private medical college described the Budhia’s med... of Government doctors who had examined the buddin... long distances. According to the report of the go...e kid’s clinical parameters such as serum urea, se...
Other Medicine News:Health News:Caffeine Content In Beverages To Be Identified By Home Test Kit 2Health News:Head Of The Church Of England Asks NHS To Respect Patient Needs 2Health News:New Home New Blessings 2
Labcold platelet incubators provide accurate and stable storage conditions at 22C. Labcold have incorporated all of the same alarm, monitoring and recording functions that are found in the Labcold BS
Mini-Incubator PC100 is compact. It is the perfect solution for small institutions, mobile units, surgery rooms.
The PC2200h contains two shelves and will hold two PF96hi agitators. It can store 192 random bags (64 apheresis bags).
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis).
Medicine Products: